Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Q3 2019 Jazz Pharmaceuticals PLC Earnings Call Transcript

Nov 05, 2019 / 09:30PM GMT
Release Date Price: $127.8 (-0.64%)
Operator

Welcome to the Jazz Pharmaceuticals plc Third Quarter 2019 Earnings Conference Call. (Operator Instructions) I will now turn the call over to Kathee Littrell, Head of Investor Relations at Jazz Pharmaceuticals.

Katherine A. Littrell
Jazz Pharmaceuticals plc - VP of IR

Thank you, Chris, and thanks to those of you joining our investor call. Today, we reported our third quarter 2019 financial results and updated our financial guidance for 2019. The press release and the slide presentation accompanying this call are available on the Investors section of our website.

On the call today are Bruce Cozadd, CEO; Dan Swisher, President; and Rob Iannone, Executive Vice President, R&D. Joining for the Q&A session are Mike Miller, Executive Vice President, U.S. Commercial; Allen Lang -- Yang, sorry, Senior Vice President, Clinical Development and Acting CMO.

And I'd also like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking. Examples of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot